Close
Arvind Sreedharan

Arvind Sreedharan, Senior Vice President, Business Operations

Arvind Sreedharan serves as Senior Vice President, Business Operations at Neurogene. Mr. Sreedharan, who leads business operations at Neurogene, has over three decades of commercial experience in the pharmaceutical and biotechnology industry, including significant experience in CNS disorders and multiple orphan diseases. Prior to Neurogene, he served as Vice President, U.S. Commercial Operations for AveXis, the gene therapy company that developed Zolgensma®, an FDA-approved treatment for spinal muscular atrophy (SMA), which was acquired by Novartis for $8.7 billion. Earlier, Mr. Sreedharan served as Vice President of Marketing at Auspex Pharmaceuticals, a biopharmaceutical company focused on hyperkinetic movement disorders and rare diseases, acquired by Teva Pharmaceutical for $3.5 billion. Before Auspex, he served as Director, Movement Disorders at Lundbeck, where he played an integral commercial role in the successful product launch and management of Xenazine®, the first FDA-approved drug for the treatment of chorea associated with Huntington’s disease. Mr. Sreedharan has supported and partnered with numerous rare disease advocacy groups throughout his career. He previously served on the Huntington’s Disease Society of America Board of Trustees and is currently a member of the Board of Directors for The Huntington Study Group (HSG), the first Huntington’s Disease cooperative therapeutic research organization and a world leader in facilitating high-quality clinical research trials and studies in Huntington’s Disease. Mr. Sreedharan holds a B.A. in both Biology and History from the University of North Carolina.